Evaluation of Toxicity Score and Precise Snake Venom Analytics for Next Generation Antivenom Development
下一代抗蛇毒血清开发的毒性评分评估和精确蛇毒分析
基本信息
- 批准号:10394860
- 负责人:
- 金额:$ 13.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibody TherapyAntidotesAntiveninsBiochemistryBiologicalBiological MarkersBiomedical ResearchBlood Coagulation DisordersBlood coagulationCellsCessation of lifeChemistryChildCollectionComplexCrotalidDataDevelopmentDoseEnzymesEscherichia coliEscherichia coli ProteinsEvaluationFacultyFoundationsFunctional disorderFutureGeographic LocationsGoalsHealthHemorrhageHumanImmune responseIndividualInjuryKnowledgeLaboratoriesLightMass Spectrum AnalysisMedicalMetabolicMetalloproteasesMethodsModelingMolecularMusNecrosisPathologyPeptidesPlasmaPlasmidsPlayProceduresPrognostic MarkerProteinsProteomicsRecombinantsReportingResearchResearch Project GrantsResearch TrainingRoleSTEM programSchoolsScienceSnake BitesSnake VenomsSnakesStructureStudentsTechnologyTestingTexasTherapeuticTimeToxic effectToxinToxinologyTrainingUniversitiesVenomsWomanacute toxicitybasecDNA Librarycareerdesigndiagnostic biomarkerexosomeexperimental studyglobal healthgraduate studentin vivoinnovationinsightinterestmembermenmethod developmentmouse modelneglected tropical diseasesnew technologynext generationnovelprogramsprotein expressionprotein purificationstatisticsstemtooltool developmenttreatment strategyundergraduate student
项目摘要
ABSTRACT
The overall goal of this project is to engage undergraduate and graduate students in innovative studies in
molecular toxinology that have the potential to contribute to important advances in our understanding of snake
venom pathology and the development of novel antibody-based therapeutics. According to WHO statistics, it is
estimated that in 2020 there will be 125,000 new deaths world-wide reported due to snake envenomation. In
spite of its importance for snake bite envenomation as a neglected tropical disease and global health issue,
very little is known of the mechanism of action of snake venom and intrinsic toxic/lethal contribution. The
scientific foundation for our study is that a specific combination of snake venom toxins plays a critical role in
snakebites by causing necrosis, coagulopathy, severe hemorrhaging and eventually death. Inasmuch as
individual toxins have been evaluated, synergistic mechanism for snake venom pathology are lacking and
warranted for antidote development. We hypothesize that precise toxicity evaluation and snake venom
analytics of crude/fractionated venom and recombinant toxins will provide a model in which priority
can be given to the most toxic venom component(s). To test our hypothesis, we will address (3) Specific
Aims: Specific Aim 1: To profile snake venom composition, combinational assessment and intrinsic
toxicity. We will purify and characterize snake venom of Crotalid snake species. Characterization will include
profiling snake venom to identify the toxins in each fraction and abundance. Students will investigate the
mechanism of action different combinations of venom fractions. We will characterize the lethal
concentrations/doses of each venom fraction on HUVEC cells, blood coagulation, and will validate the toxicity
score for each fraction using an in vivo lethality mouse model. Specific Aim 2: To produce recombinant
venom peptides. We will clone these toxins from our collection of cDNA libraries and will generate plasmids
and transform competent E.coli cells for protein expression and purification. Development of methods to
produce recombinant toxins is essential for antivenom development and investigating toxicity and targets for
medically relevant venom peptide. These studies will also be essential to use toxins in solving structures to
venom toxins or structures in complexes with known targets. Specific Aim 3: To identify snake venom
biomarkers in plasma exosomes. We will explore the “venom-reactome” using novel Evtrap technology and
proteomics in discovery-based analysis of snake venom biomarkers from mouse plasma exosomes.
Comprehensive snake venom biomarker analysis will shed new light on the pathophysiology, metabolic,
biological, cellular and immunological responses to snake venom.
抽象的
该项目的总体目标是让本科生和研究生参与创新研究
分子毒理学有可能为我们对蛇的理解做出重要贡献
根据世界卫生组织的统计数据,毒液病理学和新型抗体疗法的开发。
据估计,2020 年全球将有 125,000 人因蛇中毒而死亡。
尽管蛇咬伤作为一种被忽视的热带疾病和全球健康问题具有重要意义,
人们对蛇毒的作用机制和内在毒性/致死贡献知之甚少。
我们研究的科学基础是蛇毒毒素的特定组合在
蛇咬伤会导致坏死、凝血障碍、严重出血并最终导致死亡。
已对单个毒素进行了评估,但缺乏蛇毒病理学的协同机制
我们捕获了精确的毒性评估和蛇毒。
粗制/分馏毒液和重组毒素的分析将提供一个模型,其中优先考虑
为了检验我们的假设,我们将讨论 (3) 具体的毒液成分。
目标:具体目标 1:分析蛇毒成分、组合评估和内在特征
我们将纯化和表征响尾蛇种类的蛇毒。
分析蛇毒以确定每个组分和丰度的毒素。学生将调查蛇毒。
作用机制我们将表征毒液组分的不同组合的致命性。
每种毒液组分对 HUVEC 细胞、血液凝固的浓度/剂量,并将验证毒性
使用体内致死性小鼠模型对每个部分进行评分 具体目标 2:产生重组体。
我们将从我们的 cDNA 文库中克隆这些毒素并生成质粒。
并转化感受态大肠杆菌细胞以进行蛋白质表达和纯化的方法的开发。
生产重组毒素对于抗蛇毒血清的开发和研究毒性和目标至关重要
这些研究对于使用毒素来解决结构问题也至关重要。
具有已知目标的毒液毒素或复合物的结构。 具体目标 3:识别蛇毒。
我们将利用新型 Evtrap 技术探索“毒液反应组”。
基于发现的小鼠血浆外泌体蛇毒生物标志物分析中的蛋白质组学。
综合蛇毒生物标志物分析将为病理生理学、代谢、
对蛇毒的生物、细胞和免疫反应。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Examination of the Efficacy and Cross-Reactivity of a Novel Polyclonal Antibody Targeting the Disintegrin Domain in SVMPs to Neutralize Snake Venom.
- DOI:10.3390/toxins13040254
- 发表时间:2021-03-31
- 期刊:
- 影响因子:4.2
- 作者:Szteiter SS;Diego IN;Ortegon J;Salinas EM;Cirilo A;Reyes A;Sanchez O;Suntravat M;Salazar E;Sánchez EE;Galan JA
- 通讯作者:Galan JA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacob Anthony Galan其他文献
Crotalus lepidus Morulus ) de la roca de Tamaulipas , México
Crotalus lepidus Morulus) de la roca de Tamaulipas, 墨西哥
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
Miguel Borja;Jacob Anthony Galan;Esteban Cantu;Alejandro Zugasti;;D. Lazcano;S. Lucena;Montamas Suntravat - 通讯作者:
Montamas Suntravat
Jacob Anthony Galan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
新细胞因子FAM19A4联合CTLA-4抗体在肿瘤治疗的功能和机制研究
- 批准号:32370967
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
口服工程益生菌在体生产抗PDL1纳米抗体用于结直肠癌术后原位免疫治疗研究
- 批准号:82302366
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向肿瘤内T细胞的双特异性抗体治疗策略研究
- 批准号:82371845
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
靶向DLL3和γδ T细胞的双特异抗体对小细胞肺癌的免疫治疗活性研究
- 批准号:32300783
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
AHR促进肿瘤细胞CXCL9表达对改善肝癌PD-L1抗体治疗的作用及机制研究
- 批准号:82303142
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
开发基于 4-(芳酰氨基)哌啶的进入抑制剂作为抗流感疗法
- 批准号:
10256145 - 财政年份:2021
- 资助金额:
$ 13.8万 - 项目类别:
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
开发基于 4-(芳酰氨基)哌啶的进入抑制剂作为抗流感疗法
- 批准号:
10576494 - 财政年份:2021
- 资助金额:
$ 13.8万 - 项目类别:
Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics
开发基于 4-(芳酰氨基)哌啶的进入抑制剂作为抗流感疗法
- 批准号:
10618383 - 财政年份:2021
- 资助金额:
$ 13.8万 - 项目类别:
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells
使用 EGFRvIII 特异性 T 细胞治疗的具有调节性 T 细胞的脑肿瘤
- 批准号:
9248914 - 财政年份:2013
- 资助金额:
$ 13.8万 - 项目类别:
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells
使用 EGFRvIII 特异性 T 细胞治疗的具有调节性 T 细胞的脑肿瘤
- 批准号:
9040110 - 财政年份:2013
- 资助金额:
$ 13.8万 - 项目类别: